The coronavirus-pandemic is reshaping the biotech and pharma industry. Serum Institute of India, Bharat Biotech and Zydus Cadila and AstraZeneca of University of Oxford are in different stages in their trials in developing the vaccine. Of Course! Russia President had announced the country is first in finding vaccine race with Sputnik V. One common factor in all these companies found is making the money as early as possible with pandemic virus.
German pharmaceutical company CureVac is also joined the above. 20 year old pharma company went to listing in NASDAQ stock exchange. The share of CureVac has traded with 249% increase in its first trading day in NASDAQ. CureVac gave enormous campaign for its first IPO like “The First COVID IPO” which attracts many new investors. That causes skyrocket its share price on first day of trading. It shows how investors interest to put their money in pharmacy companies. CureVac is just one of the 170 covid-19 vaccine developed companies from US, China, UK, Russia and India. The research of CureVac is going faster than ever. In normal times new vaccine took 10 to 15 years to get into market.
CureVac expects to hit the world market by mid-2021 and price of the vaccine per dose expected around 10 to 15 Euros ($11 to $17). Investors are piling in to small, often unproven companies in hopes they can produce a vaccine in the coming months. Those companies in turn, are spending big to expand production facilities for vaccines that aren’t yet fully tested, nor certified. Now some companies have reached the clinical trial phase in a matter of months. Trusted institutions are expecting a breakthrough as early as next year. CureVac plans to produce a billion a year, if its vaccine comes to fruition. Two decades in Pharma Company made investors invest into CureVac even the company is seeking for approvals. CureVac ride on coronavirus wave in stock market.
Comments